Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Mark G. Gomez CO- Founder Canna Ventures Group LLC $MNMD

<< Previous

Bullboard Posts

Next >>

Comment by SouthernTierTomon Jun 26, 2021 9:53am

449 Views

Post# 33455778

RE:Mark G. Gomez CO- Founder Canna Ventures Group LLC $MNMD

Was anything mentioned about actually being "on" said meds in order to understand the valuation?

It sounds like the next level of what we have seen up in Canada with the Great Canadien Pot Party....how is that working out for you? ; - )

At over 2 BILLION CAD...MNMD is already pricing in wondeful clinical success and one does wonder what the actual barriers to entry are to protect such a rich valuation?

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario